Details for Patent: 11,779,572
Which drugs does patent 11,779,572 protect, and when does it expire?
Patent 11,779,572 protects QINLOCK and is included in one NDA.
Summary for Patent: 11,779,572
| Title: | Methods of treating gastrointestinal stromal tumors |
| Abstract: | The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Jing Wang, Xiaoyan Li |
| Assignee: | Deciphera Pharmaceuticals LLC |
| Application Number: | US17/938,353 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,779,572
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,779,572 | ⤷ Start Trial | TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS HAVING PRE-EXISTING SEVERE HEPATIC IMPAIRMENT AND SUFFERING FROM AN ADVERSE EVENT WHILE BEING ADMINISTERED RIPRETINIB DAILY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
